Vaxart Inc (VXRT) Stock Analysis
Verdict: WATCH (do not buy)
Temporary 2025 profitability masks a return to clinical-stage cash burn; the oral platform's potential hinges on 2028 commercialization.
Investment score: 58/100
Analysis as of
Is Vaxart Inc stock worth reviewing? The TradeMates thesis
Vaxart's oral vaccine platform is undervalued relative to peers, but the model flags a 'funding gap' risk as it reverts to losses in 2026.
7-factor investment score
- Valuation: 65/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 60/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 55/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Vaxart Inc opportunities and risks
What speaks for VXRT
- Oral Platform Differentiation
What speaks against VXRT
- Imminent Cash Burn Reversal
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| VXRT | 4.1x | 0.6x | 2.3x | 100.0% | 14.5% | 9.7% |
| HRTX | n/a | 0.9x | n/a | 71.1% | -20.5% | -15.0% |
| OKUR | n/a | 0.0x | 2.3x | 0.0% | 0.0% | -90.2% |
| SPRO | 10.8x | 3.0x | 7.9x | 100.0% | 27.8% | 4.4% |
| HURA | n/a | 0.0x | n/a | 0.0% | 0.0% | -17.6% |
| CNTB | n/a | 2826.1x | n/a | 100.0% | -58350.0% | -17.8% |
| Peer median | n/a | 0.9x | n/a | 71.1% | 0.0% | -17.6% |
Frequently asked questions about Vaxart Inc (VXRT)
Is VXRT stock a good investment?
The TradeMates model rates Vaxart Inc as WATCH (do not buy) with an investment score of 58/100. Vaxart's oral vaccine platform is undervalued relative to peers, but the model flags a 'funding gap' risk as it reverts to losses in 2026. This is algorithmic model output, not personal investment advice.
Is VXRT stock a buy?
The TradeMates model verdict for VXRT is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.